• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCOVID-19 vaccines

U.S. reaches $1.74 billion deal with Moderna for its Omicron-specific vaccine

By
Zeke Miller
Zeke Miller
and
The Associated Press
The Associated Press
Down Arrow Button Icon
By
Zeke Miller
Zeke Miller
and
The Associated Press
The Associated Press
Down Arrow Button Icon
July 29, 2022, 10:36 AM ET
Moderna COVID-19 vaccine
The U.S. is stocking up on Moderna's Omicron vaccine.Justin Sullivan—Getty Images

The Biden administration said Friday it has reached an agreement with Moderna to buy 66 million doses of the company’s next generation of COVID-19 vaccine that targets the highly transmissible Omicron variant, enough supply this winter for all who want the upgraded booster.

The order of the bivalent shot follows the announcement last month that the federal government had secured 105 million doses of a similar vaccine from rival drugmaker Pfizer. Both orders are scheduled for delivery in the fall and winter, assuming regulators sign off on their effectiveness. The Pentagon said the Moderna contract was worth $1.74 billion.

The Omicron strain has been dominant in the U.S. since December, with the BA.5 subvariant now causing a massive wave of infections across the country, even infecting President Joe Biden.

“We must stay vigilant in our fight against COVID-19 and continue to expand Americans’ access to the best vaccines and treatments,” Health and Human Services Secretary Xavier Becerra said in a statement. “As we look to the fall and winter, we’re doing just that—ensuring Americans have the tools they need to stay safe and help keep our nation moving forward.”

The U.S. orders with Pfizer and Moderna include options to purchase 300 million doses each, but reaching that total will require more funding from Congress, the Biden administration said.

About 261 million Americans have received at least one COVID-19 shot, but only 108 million have received a booster.

Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Authors
By Zeke Miller
See full bioRight Arrow Button Icon
By The Associated Press
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.